公开(公告)号：WO2007023189A2

公开(公告)日：2007-03-01

申请号：PCT/EP2006/065703

申请日：2006-08-25

Applicant: BUNDESREPUBLIK DEUTSCHLAND, VERTRETEN DURCH DAS BUNDESMINISTERIUM FÜR GESUNDHEIT, DIESES VERTRETEN DURCH DAS ROBERT-KOCH-INSTITUT ,  DENNER, Joachim ,  LANGHAMMER, Stefan ,  FIEBIG, Uwe ,  KURTH, Reinhard

Inventor： DENNER, Joachim ,  LANGHAMMER, Stefan ,  FIEBIG, Uwe ,  KURTH, Reinhard

CPC classification number: C07K16/1036 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2740/13022 ,  C12N2740/13034 ,  C12N2740/16222

Abstract: The invention relates to a pharmaceutical combined composition comprising as active ingredients an effective amount of the retroviral transmembrane envelope protein p15E of a gammaretrovirus, preferably FeLV, and an effective amount of the corresponding retroviral surface envelope protein, whereby said proteins are contained as single molecules, for inducing neutralizing antibodies which are directed against retroviral infections. The invention also relates to a method for inducing an antibody response and a method for passive immunization of a mammal by using neutralizing antibodies which are generated by administering said pharmaceutical composition.

Abstract translation: 本发明涉及一种药物组合组合物，其包含作为有效成分的有效量的瘤胃转录病毒的逆转录病毒跨膜包膜蛋白p15E，优选为FeLV，以及有效量的相应的逆转录病毒表面包膜蛋白，由此所述蛋白质作为单一分子包含， 用于诱导针对逆转录病毒感染的中和抗体。 本发明还涉及通过使用通过施用所述药物组合物产生的中和抗体来诱导抗体应答的方法和哺乳动物的被动免疫方法。

公开(公告)号：WO01043771A1

公开(公告)日：2001-06-21

申请号：PCT/FR2000/003526

申请日：2000-12-14

IPC: A61K9/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61P35/00 ,  A61P37/02 ,  C07K16/10 ,  C07K16/18

CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

Abstract: The invention concerns the use of a protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment of said protein, said protein being initially an immunosuppressive and/or an angiogenic protein with local activity whereof said properties have been inactivated by at least 70 % by a physical and/or chemical treatment, such as formolisation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralising or blocking said native protein, or the use of a DNA molecule corresponding to said protein inactivated by mutation or to said inactive fragment, for obtaining a medicine designed to provide a patient with mucosal immunity based on secretion of IgA secretory antibodies, pharmaceutical compositions for the mucous membranes and IgA antibodies.

Abstract translation: 本发明涉及使用衍生自癌细胞的蛋白质，被病毒或免疫细胞感染的细胞或所述蛋白质的无活性片段，所述蛋白质最初是免疫抑制剂和/或具有局部活性的血管生成蛋白质，其中所述性质已被灭活 通过物理和/或化学处理如至少70％，通过基本重组或通过辅助调理来形成，例如甲酰化，羧甲酰化，羧甲基化，马来酰亚胺化或氧化，所述处理保持其被针对所述 蛋白质，并且保留足够的免疫原性，产生中和或阻断所述天然蛋白质的抗体，或使用对应于通过突变而灭活的所述蛋白质的DNA分子或所述非活性片段获得旨在为患者提供基于粘膜免疫的药物 对IgA分泌抗体的分泌，药物组合物 适用于粘膜和IgA抗体。

公开(公告)号：WO1992013946A1

公开(公告)日：1992-08-20

申请号：PCT/US1992000823

申请日：1992-02-03

Applicant: GENELABS INCORPORATED

Inventor： GENELABS INCORPORATED ,  REYES, Gregory, R. ,  HADLOCK, Kenneth, G.

IPC: C12N15/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/1036 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2740/14022 ,  Y10S435/974 ,  Y10S435/975

Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp 46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.

Abstract translation: 公开了新型HTLV-1和HTLV-II肽抗原用于筛选和确认HTLV-1和HTLV-II抗血清的诊断测定。 肽衍生自HTLV-1和HTLV-II gp 46包膜蛋白的类似区域，并通过其与HTLV-II特异性单克隆抗体和HTLV-1和HTLV-II抗血清的免疫反应性来区分。 肽也可用于疫苗组合物。

公开(公告)号：WO9014427A3

公开(公告)日：1991-01-10

申请号：PCT/EP9000831

申请日：1990-05-23

Applicant: SANDOZ LTD ,  UNIV DUKE

Inventor： BACHMAYER HELMUT ,  BOEHNLEIN ERNST ,  CULLEN BRYAN R ,  GREENE WARNER C ,  HAUBER JOACHIM

IPC: C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61K39/21 ,  A61K48/00 ,  A61P31/12 ,  A61P31/18 ,  A61P37/04 ,  C07K14/00 ,  C07K14/005 ,  C07K14/15 ,  C07K14/155 ,  C07K14/16 ,  C07K14/195 ,  C07K16/10 ,  C12N5/00 ,  C12N5/10 ,  C12N7/00 ,  C12N15/49 ,  C12P21/02 ,  C12Q1/68 ,  C12R1/91

CPC classification number: C07K16/1036 ,  A61K38/00 ,  C07K14/005 ,  C12N2740/14022 ,  C12N2740/16322

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-I and corresponding mutated genes are described, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used. Some of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species. Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.

公开(公告)号：US20190010238A1

公开(公告)日：2019-01-10

申请号：US16031418

申请日：2018-07-10

Applicant: NEW YORK UNIVERSITY

Inventor： Thomas WISNIEWSKI ,  Allal BOUTAJANGOUT

IPC: C07K16/28 ,  C07K16/10 ,  A61P25/28 ,  A61P25/18

CPC classification number: C07K16/2872 ,  A61K2039/505 ,  A61P25/18 ,  A61P25/28 ,  C07K16/1036 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/34

Abstract: The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

公开(公告)号：US08541553B2

公开(公告)日：2013-09-24

申请号：US12601780

申请日：2008-05-23

Applicant: Johannes Humer ,  Bernd Mayer ,  Thomas Muster ,  Andrea Waltenberger

Inventor： Johannes Humer ,  Bernd Mayer ,  Thomas Muster ,  Andrea Waltenberger

IPC: C07K16/00 ,  C12N5/07 ,  A61K39/42 ,  A61K39/21

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

Abstract translation: 本发明提供用于分离和/或鉴定内源性逆转录病毒，优选黑素瘤相关内源性逆转录病毒的表位的抗体或其片段，以及产生所述抗体的杂交瘤细胞。 抗体特别适用于癌症的治疗和诊断。 此外，本申请包括用于检测癌细胞，特别是黑素瘤细胞的诊断试剂盒和使用所述抗体的癌症诊断方法。

公开(公告)号：US20120171235A1

公开(公告)日：2012-07-05

申请号：US13414356

申请日：2012-03-07

Applicant: Xiaoxing Qiu ,  John R. Hackett, JR. ,  Ka-Cheung X. Luk ,  Priscilla Swanson

Inventor： Xiaoxing Qiu ,  John R. Hackett, JR. ,  Ka-Cheung X. Luk ,  Priscilla Swanson

IPC: A61K39/21 ,  A61P31/14 ,  A61P37/04

CPC classification number: C07K16/1036 ,  A61K39/00 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C12N2740/13022

Abstract: The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities.

Abstract translation: 本发明一般涉及用于检测嗜酸性白血病病毒相关逆转录病毒（“XMRV”）和与XMRV感染有关的疾病的检测方法。 此外，本发明涉及能够诱导免疫原性应答的特异性XMRV抗原以及具有显着诊断，筛选和治疗效用的XMRV相关核酸。

公开(公告)号：US20110243962A1

公开(公告)日：2011-10-06

申请号：US12997486

申请日：2009-07-08

Applicant: Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

Inventor： Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

IPC: A61K39/42 ,  C07K16/10 ,  C07H21/04 ,  A61P37/04 ,  A61P31/12 ,  A61P25/00 ,  A61P25/18 ,  A61P17/06 ,  A61P35/00 ,  A61P3/10 ,  C12N15/63 ,  C12P21/02 ,  G01N33/566 ,  C12N5/10

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

Abstract translation: 本发明涉及包含SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5所示的每个互补决定区（CDR）和 SEQ ID No.6或在所述序列中具有任意数目的取代氨基酸的序列，如下所示，CDR1（SEQ ID No.1）中为0至3，CDR2（SEQ ID No.2）为0至2， 在CDR3（SEQ ID No.3）中为0至2，CDR4（SEQ ID No.4）为0至1，CDR5（SEQ ID No.5）为0至4，CDR6（SEQ ID NO：0）为0至2 SEQ ID NO：6），或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。

公开(公告)号：US07666420B2

公开(公告)日：2010-02-23

申请号：US10586742

申请日：2005-01-24

Applicant: Patrice Marche ,  Alexandre Rolland ,  Evelyne Jouvin-Marche ,  Herve Perron

Inventor： Patrice Marche ,  Alexandre Rolland ,  Evelyne Jouvin-Marche ,  Herve Perron

IPC: A61K39/395 ,  A61K39/42 ,  C07K16/00 ,  C07K16/08 ,  C12P21/08

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/1036

Abstract: The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV/HERV-W.

Abstract translation: 本发明的组合物包含选自抗-Env-SU MSRV / HERV-W抗体组（i）中的至少一种类型的抗体或与MSRV的Env蛋白的可溶性部分特异性连接的一组抗TLR4抗体 / HERV-W或MSRV / HERV-W的Env蛋白的可溶性级分的TLR4受体。

公开(公告)号：US20090130129A1

公开(公告)日：2009-05-21

申请号：US11914098

申请日：2006-05-11

Applicant: Bernd Mayer ,  Johannes Humer ,  Thomas Muster ,  Andrea Waltenberger

Inventor： Bernd Mayer ,  Johannes Humer ,  Thomas Muster ,  Andrea Waltenberger

IPC: A61K39/00 ,  C07K7/00 ,  C07K16/18 ,  G01N33/566 ,  G01N33/53 ,  G01N33/574

CPC classification number: A61K38/162 ,  A61K39/00 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/1036 ,  C07K2317/34 ,  C12N2740/10022 ,  G01N33/5743 ,  G01N2333/15 ,  G01N2469/20

Abstract: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.

Abstract translation: 本发明提供衍生自黑素瘤相关内源性逆转录病毒（MERV）的抗原多肽。 这些抗原是检测癌细胞和黑素瘤诊断以及黑素瘤预后的有用化合物。 此外，本发明的这些抗原多肽形成抗癌疫苗的基础。